1. Home
  2. SPB vs URGN Comparison

SPB vs URGN Comparison

Compare SPB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spectrum Brands Holdings Inc.

SPB

Spectrum Brands Holdings Inc.

HOLD

Current Price

$90.69

Market Cap

2.0B

Sector

Miscellaneous

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$48.12

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPB
URGN
Founded
1906
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
SPB
URGN
Price
$90.69
$48.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$82.40
$29.29
AVG Volume (30 Days)
342.0K
871.5K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
2.31%
N/A
EPS Growth
N/A
N/A
EPS
1.01
N/A
Revenue
$3,802,100,000.00
$1,128,000.00
Revenue This Year
$2.03
$129.09
Revenue Next Year
$1.85
$70.96
P/E Ratio
$87.54
N/A
Revenue Growth
20.86
N/A
52 Week Low
$49.99
$15.86
52 Week High
$99.06
$49.67

Technical Indicators

Market Signals
Indicator
SPB
URGN
Relative Strength Index (RSI) 57.53 67.47
Support Level $79.63 $18.23
Resistance Level $90.60 N/A
Average True Range (ATR) 3.06 2.45
MACD -0.22 0.45
Stochastic Oscillator 33.47 86.68

Price Performance

Historical Comparison
SPB
URGN

About SPB Spectrum Brands Holdings Inc.

Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: